Medical Devices

63 tickers in this theme
NewestHighest Score Ranks all matching reports in this category by score, highest first.
IDEX Corporation
IEX·Industrials
A ★★★★Buy
Current$233.84
Target$252.50
Return+8.0%
Oct 31, 2026

IDEX combines high-margin niche industrial franchises, strong cash conversion, and improving organic demand to compound earnings, although premium valuation and acquisition execution risks limit its margin of safety.

Score
75
Becton, Dickinson and Company
BDX·Healthcare
B ★★★Hold
Current$211.88
Target$217.80
Return+2.8%
Nov 8, 2026

Becton Dickinson combines recurring medical-device demand, strong cash generation, and post-separation efficiency potential, but modest organic growth, leverage, and the recent stock-price recovery constrain near-term upside.

Score
74
Edwards Lifesciences Corporation
EW·Healthcare
B ★★★Hold
Current$102.14
Target$103.50
Return+1.3%
Nov 7, 2026

Edwards Lifesciences combines a durable TAVR franchise with fast-growing mitral and tricuspid therapies, but demanding cash-flow valuation and competition limit near-term upside despite strong clinical momentum.

Score
73
Boston Scientific Corporation
BSX·Healthcare
B ★★★Hold
Current$41.98
Target$51.20
Return+22.0%
Oct 31, 2026

Boston Scientific offers specialized medical-device franchises, strong cash generation, and recovery potential at a discounted valuation, but cardiovascular weakness, cybersecurity disruption, and Penumbra financing threaten near-term earnings growth.

Score
73
Thermo Fisher Scientific Inc.
TMO·Healthcare
B ★★★Hold
Current$673.82
Target$721.24
Return+7.0%
Oct 25, 2026

Thermo Fisher Scientific combines durable laboratory switching costs, recurring consumables, and recovering biopharma demand with strong cash generation, but demanding valuation and acquisition-related leverage limit near-term upside.

Score
73
Teleflex Incorporated
TFX·Healthcare
B ★★★Hold
Current$150.87
Target$164.10
Return+8.8%
Nov 8, 2026

Teleflex could unlock higher per-share earnings through portfolio simplification, debt reduction, and medical device innovation, but weak capital returns and uncertain recurring margins constrain the investment case.

Score
72
ICU Medical, Inc.
ICUI·Healthcare
B ★★★Hold
Current$172.11
Target$183.35
Return+6.5%
Nov 8, 2026

ICU Medical offers a credible infusion-therapy turnaround supported by recurring consumables and stronger cash flow, but modest ROIC, acquisition-related debt, and product-quality risks limit its margin of safety.

Score
72
Baxter International Inc.
BAX·Healthcare
B ★★★Hold
Current$23.00
Target$27.30
Return+18.7%
Nov 1, 2026

Baxter offers a discounted medical-products turnaround supported by recurring hospital demand, recovering cash flow and debt reduction, but elevated leverage and uncertain margin sustainability limit near-term conviction.

Score
72
Haemonetics Corporation
HAE·Healthcare
B ★★★Hold
Current$119.93
Target$127.16
Return+6.0%
Nov 8, 2026

Haemonetics offers recurring plasma disposables, improving cash generation, and new vascular closure growth opportunities, but its elevated historical valuation and CSL rollout dependence limit near-term upside.

Score
71
Bio-Rad Laboratories, Inc.
BIO·Healthcare
B ★★★Hold
Current$381.57
Target$397.83
Return+4.3%
Nov 7, 2026

Bio-Rad combines resilient clinical diagnostics, improving adjusted margins, and a valuable Sartorius stake, but weak Life Science demand and low operating returns limit near-term upside.

Score
71
Cardinal Health, Inc.
CAH·Healthcare
B ★★★Hold
Current$271.72
Target$258.00
Return-5.0%
Nov 8, 2026

Cardinal Health's entrenched pharmaceutical distribution network and expanding specialty services support durable earnings growth, but its historically elevated valuation and customer concentration limit near-term upside.

Score
70
Glaukos Corporation
GKOS·Healthcare
B ★★★Hold
Current$237.60
Target$208.45
Return-12.3%
Nov 2, 2026

Glaukos combines accelerating ophthalmic treatment adoption, differentiated clinical technology, and emerging profitability, but its premium valuation leaves limited room for commercialization or earnings disappointments.

Score
70